Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P240011/S016

Altaviva

Medtronic Neuromodulation · Decision date Sep 14, 2026

MEDTECHLEDGER EXPLANATIONP240011/S016

What did the FDA decide?

The FDA database entry records a 30-day notice for Altaviva (P240011/S016), decided OK30 on 2026-09-14. The supplement type is a 30-day notice with reason Process Change - Manufacturer/Sterilizer/Packager/Supplier, and the stated change is "the addition of a manufacturing verification step for the WR9220A and P720R1 wireless rechargers." The source identifies the device category as an implantable tibial electrical stimulator for urinary incontinence, product code QPT, specialties gastroenterology and urology, and the applicant as Medtronic Neuromodulation.

The supplement number tied to PMA P240011 establishes that this notice falls under that original approval rather than constituting a new PMA. The statement covers only an added manufacturing verification step for two named recharger models; it does not describe the verification method, acceptance criteria, affected manufacturing sites, or any clinical data. A reported process-change purpose is not independent evidence of safety or clinical effectiveness, and no new indication or clinical outcome is stated here.

FDA approval order statement

the addition of a manufacturing verification step for the WR9220A and P720R1 wireless rechargers
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Gastroenterology, Urology
Decision date
Sep 14, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P240011/S016
Regulatory pathway
PMA supplement
Product code
QPT
Decision code
OK30
Decision date
Sep 14, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Stimulator, tibial, electrical, implantable, for urinary incontinence.

Product code
QPT
FDA device class
3

For the original device and its historical approval scope, see PMA P240011. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P240011 · Original PMA

    Medtronic Altaviva System

  2. P240011/S016 received

    Application receipt date recorded by FDA.

  3. P240011/S016 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P240011. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P240011

Product / regulatory recordCompanyPathwayDecision dateSource
Medtronic NeuromodulationPMA approvalSep 18, 2025FDA

Explore the linked device profile

Other records with product code QPT

Product / regulatory recordCompanyPathwayDecision dateSource
BOSTON SCIENTIFIC CORPORATIONPMA supplementSep 9, 2026FDA
BOSTON SCIENTIFIC CORPORATIONPMA approvalMar 1, 2022FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Medtronic Neuromodulation

Headquarters
Not reported
Brand website
medtronic.com
FDA applicant address
7000 Central Ave. NE, Ms Rce480, Minneapolis, MN, 55432

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records